Rosen Law Firm is soliciting investors to join securities class action lawsuits against Commvault Systems, ChampionX Corporation, and Regencell Bioscience Holdings. The firm reminds investors of upcoming lead plaintiff deadlines and offers contingency-based legal representation. The lawsuits allege that defendants made materially false statements and concealed adverse facts regarding financial performance.

Rosen Law Firm is reminding investors in Regencell Bioscience Holdings Limited, ChampionX Corporation, and Commvault Systems, Inc. of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities, regulatory risks, and other material misstatements that caused investor damages.

Ten large-cap stocks experienced significant declines during the week of May 25-29, 2026. Zscaler led losses with a 20.06% drop following disappointing Q3 results and weak Q4 guidance. Other major losers included Boston Scientific (16.95%), AutoZone (14.21%), Regencell Bioscience (12.61%), and Venture Global (10.87%). Declines were attributed to earnings misses, analyst downgrades, and energy sector weakness following geopolitical developments.

A class action lawsuit has been filed against Regencell Bioscience Holdings Limited (NASDAQ: RGC) in the U.S. District Court for the District of Maryland. The lawsuit alleges that the company made false and misleading statements regarding its vulnerability to market manipulation, resulting volatility in its ordinary shares, and exposure to regulatory scrutiny and enforcement action. Investors who purchased Regencell securities between October 28, 2024 and October 31, 2025 have until June 23, 2026 to apply to be appointed as lead plaintiff.

Rosen Law Firm has filed securities class action lawsuits against Regencell Bioscience Holdings Limited, FS KKR Capital Corp., and New Era Energy & Digital, Inc. Investors who purchased securities during specified class periods and suffered losses exceeding $100,000 are encouraged to join the litigation before upcoming deadlines. The lawsuits allege false and misleading statements regarding market manipulation, regulatory risks, and financial disclosures.

Rosen Law Firm is notifying investors in Gossamer Bio, Inc., FS KKR Capital Corp., and Regencell Bioscience Holdings Limited of ongoing securities class action lawsuits. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the June 1, 2026 deadline. The Gossamer case alleges defendants made false statements about their Phase 3 PROSERA study design while concealing material adverse facts.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Regencell Bioscience Holdings Limited (RGC), where investors who purchased securities between October 28, 2024 and October 31, 2025 may be entitled to compensation. The lawsuit alleges that Regencell made false statements and failed to disclose vulnerabilities to market manipulation and regulatory risks. The lead plaintiff deadline is June 23, 2026.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against three companies: Regencell Bioscience Holdings (RGC) for alleged false statements regarding market manipulation vulnerability, SES AI Corporation (SES) for misrepresentations about business and growth prospects, and POET Technologies Inc. (POET) for alleged false disclosures regarding tax status. Investors who purchased shares during the specified periods and suffered losses are encouraged to seek legal representation.

Rosen Law Firm is notifying investors about ongoing securities class action lawsuits against Regencell Bioscience Holdings Limited, Medpace Holdings, Inc., and Gossamer Bio, Inc. The firm is seeking lead plaintiffs with a June 23, 2026 deadline. Investors who purchased securities during specified class periods may be eligible for compensation through contingency fee arrangements.

Class action lawsuits have been filed against three publicly-traded companies alleging securities fraud. Regencell Bioscience (RGC) faces allegations of market manipulation vulnerability, SES AI (SES) is accused of overstating business prospects and creating false revenue appearances, and FS KKR Capital Corp. (FSK) is charged with overstating portfolio valuations and restructuring effectiveness. Investors have until late June/early July 2026 to file lead plaintiff motions.

A class action lawsuit has been filed against Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) alleging that company defendants made materially false and misleading statements regarding the company's business operations and compliance policies. The complaint claims Regencell was vulnerable to market manipulation and failed to disclose associated risks to investors. The class period covers purchases between October 28, 2024 and October 31, 2025, with a lead plaintiff deadline of June 23, 2026.

A class action lawsuit has been filed against Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) alleging that company defendants made materially false and misleading statements regarding the company's vulnerability to market manipulation, resulting volatility, and exposure to regulatory scrutiny. Investors who purchased Regencell securities between October 28, 2024 and October 31, 2025 are encouraged to join the case, with a lead plaintiff deadline of June 23, 2026.